Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.
Prediction: This Will be Eli Lilly's Next Big Move.
Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring sales thanks to its dominance in the high-growth weight loss drug market. This is thanks to Lilly's dominance in the billion-dollar weight loss drug market.
Eli Lilly & Co: Maintaining Market Dominance with Orforglipron Amid Competitor Challenges
Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Eli Lilly and Company’s LLY stock has risen 21.1% in six months compared with an increase of 10.5% for the industry. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below.
Eli Lilly and Company (LLY): Among Morgan Stanley’s Best Stock Picks for 2025
We recently compiled a list of Morgan Stanley’s Best Stock Picks: 15 Stocks To Own For 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Morgan Stanley’s other stock picks.
Eli Lilly & Co. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and currently trading at $905.00. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,
12h
Eli Lilly Is Finally Cheap, Warranting An Upgrade To Buy
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
11d
on MSN
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...
1d
on MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
18h
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
14h
Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline
In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...
Ibj.com
3d
Eli Lilly requests records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
1d
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Investor's Business Daily on MSN
13h
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
New York Stock Exchange
Novo Nordisk
Feedback